1
|
Blöchl C, Gstöttner C, Sénard T, Stork EM, Scherer HU, Toes REM, Wuhrer M, Domínguez-Vega E. A robust nanoscale RP HPLC-MS approach for sensitive Fc proteoform profiling of IgG allotypes. Anal Chim Acta 2023; 1279:341795. [PMID: 37827688 DOI: 10.1016/j.aca.2023.341795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 08/30/2023] [Accepted: 09/06/2023] [Indexed: 10/14/2023]
Abstract
The conserved region (Fc) of IgG antibodies dictates the interactions with designated receptors thus defining the immunological effector functions of IgG. Amino acid sequence variations in the Fc, recognized as subclasses and allotypes, as well as post-translational modifications (PTMs) modulate these interactions. Yet, the high similarity of Fc sequences hinders allotype-specific PTM analysis by state-of-the-art bottom-up methods and current subunit approaches lack sensitivity and face co-elution of near-isobaric allotypes. To circumvent these shortcomings, we present a nanoscale reversed-phase (RP) HPLC-MS workflow of intact Fc subunits for comprehensive characterization of Fc proteoforms in an allotype- and subclass-specific manner. Polyclonal IgGs were purified from individuals followed by enzymatic digestion releasing single chain Fc subunits (Fc/2) that were directly subjected to analysis. Chromatographic conditions were optimized to separate Fc/2 subunits of near-isobaric allotypes and subclasses allowing allotype and proteoform identification and quantification across all four IgG subclasses. The workflow was complemented by a semi-automated data analysis pipeline based on the open-source software Skyline followed by post-processing in R. The approach revealed pronounced differences in Fc glycosylation between donors, besides inter-subclass and inter-allotype variability within donors. Notably, partial occupancy of the N-glycosylation site in the CH3 domain of IgG3 was observed that is generally neglected by established approaches. The described method was benchmarked across several hundred runs and showed good precision and robustness. This methodology represents a first mature Fc subunit profiling approach allowing truly subclass- and allotype-specific Fc proteoform characterization beyond established approaches. The comprehensive information obtained paired with the high sensitivity provided by the miniaturization of the approach guarantees applicability to a broad range of research questions including clinically relevant (auto)antibody characterization or pharmacokinetics assessment of therapeutic IgGs.
Collapse
Affiliation(s)
- Constantin Blöchl
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands
| | - Christoph Gstöttner
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands
| | - Thomas Sénard
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands
| | - Eva Maria Stork
- Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands
| | - Hans Ulrich Scherer
- Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands
| | - Rene E M Toes
- Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands
| | - Manfred Wuhrer
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands
| | - Elena Domínguez-Vega
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
| |
Collapse
|
2
|
Ruppen I, Beydon ME, Solís C, Sacristán D, Vandenheede I, Ortiz A, Sandra K, Adhikary L. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization. Biologicals 2022; 77:1-15. [DOI: 10.1016/j.biologicals.2021.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 08/26/2021] [Accepted: 08/29/2021] [Indexed: 11/02/2022] Open
|
3
|
Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization. Biologicals 2021; 73:41-56. [PMID: 34593306 DOI: 10.1016/j.biologicals.2021.09.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
The majority of recombinant mAb products contain heterogeneous charge variants, commonly the result of post-translational modifications occurring during cell culture and accumulated during production, formulation and storage. MB02 is a biosimilar mAb to bevacizumab. Similarity data of charge variants for biosimilars against its reference products must be generated to demonstrate consistency in product quality and to ensure efficacy and safety. The goal of this work was to isolate seven charge variants of MB02 and Avastin® by semi-preparative cation exchange chromatography followed by purity test and extended analytical characterization to prove similarity. Although poor purity obtained for minor variants complicated data interpretation, an in-depth insight into the charge variants pattern of MB02 compared to Avastin® was obtained, contributing to a better understanding of modifications associated to microheterogeneity. To our knowledge, this is the first comparative analytical study of individual charge variants of a bevacizumab biosimilar following a head-to head approach and the most comprehensive N-glycosylation assessment of IgG1 charge variants. Although modifications related to N- and C-terminal, N-glycans, size heterogeneity or deamidation were specifically enriched among low abundant charge variants, they did not affect binding affinity to VEGF or FcRn and in vitro potency compared with the main species or unfractionated material.
Collapse
|
4
|
Wang D, Nowak C, Mason B, Katiyar A, Liu H. Analytical artifacts in characterization of recombinant monoclonal antibody therapeutics. J Pharm Biomed Anal 2020; 183:113131. [DOI: 10.1016/j.jpba.2020.113131] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 01/22/2020] [Accepted: 01/24/2020] [Indexed: 01/12/2023]
|
5
|
Kang J, Halseth T, Vallejo D, Najafabadi ZI, Sen KI, Ford M, Ruotolo BT, Schwendeman A. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars. Anal Bioanal Chem 2019; 412:763-775. [DOI: 10.1007/s00216-019-02298-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Revised: 11/03/2019] [Accepted: 11/21/2019] [Indexed: 10/25/2022]
|
6
|
A generic method for intact and subunit level characterization of mAb charge variants by native mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1133:121814. [DOI: 10.1016/j.jchromb.2019.121814] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Revised: 09/19/2019] [Accepted: 09/23/2019] [Indexed: 01/16/2023]
|
7
|
Performance Comparison of a Laterally-Fed Membrane Chromatography (LFMC) Device with a Commercial Resin Packed Column. MEMBRANES 2019; 9:membranes9110138. [PMID: 31671843 PMCID: PMC6918161 DOI: 10.3390/membranes9110138] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Revised: 10/17/2019] [Accepted: 10/24/2019] [Indexed: 11/17/2022]
Abstract
The use of conventional membrane adsorbers such as radial flow devices is largely restricted to flow-through applications, such as virus and endotoxin removal, as they fail to give acceptable resolution in bind-and-elute separations. Laterally-fed membrane chromatography or LFMC devices have been specifically developed to combine high-speed with high-resolution. In this study, an LFMC device containing a stack of strong cation exchange membranes was compared with an equivalent resin packed column. Preliminary characterization experiments showed that the LFMC device had a significantly greater number of theoretical plates per metre than the column. These devices were used to separate a ternary model protein mixture consisting of ovalbumin, conalbumin and lysozyme. The resolution obtained with the LFMC device was better than that obtained with the column. For instance, the LFMC device could resolve lysozyme dimer from lysozyme monomer, which was not possible using the column. In addition, the LFMC device could be operated at lower pressure and at significantly higher flow rates. The devices were then compared based on an application case study, i.e., preparative separation of monoclonal antibody charge variants. The LFMC device gave significantly better separation of these variants than the column.
Collapse
|
8
|
Liu P, Zhu X, Wu W, Ludwig R, Song H, Li R, Zhou J, Tao L, Leone AM. Subunit mass analysis for monitoring multiple attributes of monoclonal antibodies. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2019; 33:31-40. [PMID: 30286260 DOI: 10.1002/rcm.8301] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/09/2018] [Revised: 09/26/2018] [Accepted: 09/29/2018] [Indexed: 06/08/2023]
Abstract
RATIONALE Multi-Attribute Methods (MAMs) are appealing due to their ability to provide data on multiple molecular attributes from a single assay. If fully realized, such tests could reduce the number of assays required to support a product control strategy while providing equivalent or greater product understanding relative to the conventional approach. In doing so, MAMs have the potential to decrease development and manufacturing costs by reducing the number of tests in a release panel. METHODS In this work, we report a MAM which is based on subunit mass analysis. RESULTS The MAM assay is shown to be suitable for use as a combined method for identity testing, glycan profiling, and protein ratio determination for co-formulated monoclonal antibody (mAb) drugs. This is achieved by taking advantage of the high mass accuracy and relative quantification capabilities of intact mass analysis using quadrupole time-of-flight mass spectrometry (Q-TOF MS). Protein identification is achieved by comparing the measured masses of light chain (LC) and heavy chain (HC) mAbs against their theoretical values. Specificity is based on instrument mass accuracy. Glycan profiling and relative protein ratios are determined by the relative peak intensities of the protein HC glycoforms and LC glycoforms, respectively. Results for these relative quantifications agree well with those obtained by the conventional hydrophilic interaction liquid chromatography (HILIC) and reversed-phase LC methods. CONCLUSIONS The suitability of this MAM for use in a quality control setting is demonstrated through assessment specificity for mAb identity, and accuracy, precision, linearity and robustness for glycan profiling and ratio determination. Results from this study indicate that a MAM with subunit mass analysis has the potential to replace three conventional methods widely used for mAb release testing including identification assay, glycosylation profiling, and ratio determination for co-formulated mAbs.
Collapse
Affiliation(s)
- Peiran Liu
- Molecular and Analytical Development, Bristol-Myers Squibb, Pennington, NJ, 08534, USA
| | - Xin Zhu
- Agilent Technologies, Wilmington, DE, USA
| | - Wei Wu
- Molecular and Analytical Development, Bristol-Myers Squibb, Pennington, NJ, 08534, USA
| | - Richard Ludwig
- Molecular and Analytical Development, Bristol-Myers Squibb, Pennington, NJ, 08534, USA
| | - Hangtian Song
- Molecular and Analytical Development, Bristol-Myers Squibb, Pennington, NJ, 08534, USA
| | - Ruojia Li
- Molecular and Analytical Development, Bristol-Myers Squibb, Pennington, NJ, 08534, USA
| | - Jiping Zhou
- Global Product Development and Supply, Bristol-Myers Squibb, New Brunswick, NJ, 08903, USA
| | - Li Tao
- Molecular and Analytical Development, Bristol-Myers Squibb, Pennington, NJ, 08534, USA
| | - Anthony M Leone
- Molecular and Analytical Development, Bristol-Myers Squibb, Pennington, NJ, 08534, USA
| |
Collapse
|
9
|
Dai J, Zhang Y. A Middle-Up Approach with Online Capillary Isoelectric Focusing/Mass Spectrometry for In-Depth Characterization of Cetuximab Charge Heterogeneity. Anal Chem 2018; 90:14527-14534. [DOI: 10.1021/acs.analchem.8b04396] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Jun Dai
- Separation and Analysis Technology Team, Bristol-Myers Squibb Research and Development, Post Office
Box 4000, Princeton, New Jersey 08543, United States
| | - Yingru Zhang
- Separation and Analysis Technology Team, Bristol-Myers Squibb Research and Development, Post Office
Box 4000, Princeton, New Jersey 08543, United States
| |
Collapse
|
10
|
Grassi L, Roschger C, Stanojlović V, Cabrele C. An explorative study towards the chemical synthesis of the immunoglobulin G1 Fc CH3 domain. J Pept Sci 2018; 24:e3126. [PMID: 30346065 PMCID: PMC6646916 DOI: 10.1002/psc.3126] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2018] [Revised: 08/26/2018] [Accepted: 09/06/2018] [Indexed: 12/16/2022]
Abstract
Monoclonal antibodies, fusion proteins including the immunoglobulin fragment c (Ig Fc) CH2‐CH3 domains, and engineered antibodies are prominent representatives of an important class of drugs and drug candidates, which are referred to as biotherapeutics or biopharmaceuticals. These recombinant proteins are highly heterogeneous due to their glycosylation pattern. In addition, enzyme‐independent reactions, like deamidation, dehydration, and oxidation of sensitive side chains, may contribute to their heterogeneity in a minor amount. To investigate the biological impact of a spontaneous chemical modification, especially if found to be recurrent in a biotherapeutic, it would be necessary to reproduce it in a homogeneous manner. Herein, we undertook an explorative study towards the chemical synthesis of the IgG1 Fc CH3 domain, which has been shown to undergo spontaneous changes like succinimide formation and methionine oxidation. We used Fmoc‐solid‐phase peptide synthesis (SPPS) and native chemical ligation (NCL) to test the accessibility of large fragments of the IgG1 Fc CH3 domain. In general, the incorporation of pseudoproline dipeptides improved the quality of the crude peptide precursors; however, sequences larger than 44 residues could not be achieved by standard stepwise elongation with Fmoc‐SPPS. In contrast, the application of NCL with cysteine residues, which were either native or introduced ad hoc, allowed the assembly of the C‐terminal IgG1 Fc CH3 sequence 371 to 450. The syntheses reported here show advantages and limitations of the chemical approaches chosen for the preparation of the synthetic IgG1 Fc CH3 domain and will guide future plans towards the synthesis of both the native and selectively modified full‐length domain.
Collapse
Affiliation(s)
- Luigi Grassi
- Christian Doppler Laboratory for Innovative Tools for Biosimilar Characterization, University of Salzburg, Hellbrunner Strasse 34, 5020, Salzburg, Austria.,Department of Biosciences, University of Salzburg, Billrothstrasse 11, 5020, Salzburg, Austria
| | - Cornelia Roschger
- Department of Biosciences, University of Salzburg, Billrothstrasse 11, 5020, Salzburg, Austria
| | - Vesna Stanojlović
- Department of Biosciences, University of Salzburg, Billrothstrasse 11, 5020, Salzburg, Austria
| | - Chiara Cabrele
- Christian Doppler Laboratory for Innovative Tools for Biosimilar Characterization, University of Salzburg, Hellbrunner Strasse 34, 5020, Salzburg, Austria.,Department of Biosciences, University of Salzburg, Billrothstrasse 11, 5020, Salzburg, Austria
| |
Collapse
|
11
|
Sankaran PK, Kabadi PG, Honnappa CG, Subbarao M, Pai HV, Adhikary L, Palanivelu DV. Identification and quantification of product-related quality attributes in bio-therapeutic monoclonal antibody via a simple, and robust cation-exchange HPLC method compatible with direct online detection of UV and native ESI-QTOF-MS analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1102-1103:83-95. [PMID: 30380467 DOI: 10.1016/j.jchromb.2018.10.019] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 10/14/2018] [Accepted: 10/19/2018] [Indexed: 02/03/2023]
Abstract
Modern analytical ion-exchange chromatography is one of the conventional tools used for assessment of product-related quality attributes in bio-therapeutic monoclonal antibodies (mAbs). Here, we present an approach to resolve, identify, and quantify product-related substances of therapeutic mAb at its intact molecular level by cation exchange (CIEX) HPLC coupled directly to electrospray ionization - quadrupole time of flight mass spectrometry (ESI-QTOF-MS). This method utilizes pH gradient elution mode comprised of ammonium formate buffer components, and a weak cation exchange column as stationary phase. Furthermore, ion-mobility mass spectrometry (IM-MS) provided additional insights on its higher order structure. Also, orthogonal assays such as conventional CIEX-HPLC, high resolution capillary isoelectric focusing, peptide mapping, spectroscopic, and fluorescence methods were used considerably to support the findings. Additionally, an in vitro assay was included to assess the associated impact on Fc mediated function. Overall, the developed method with simultaneous detection of UV peak area percentage at 280 nm and native ESI-MS is found to be a rapid and robust analytical tool for direct assessment of structural and purity attributes, process optimization, product development, and to decipher the relevant role of micro-variants on quality, stability, and clinical outcomes.
Collapse
Affiliation(s)
- Praveen Kallamvalliillam Sankaran
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India.
| | - Pradeep G Kabadi
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| | - Chethan Gejjalagere Honnappa
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| | - Malini Subbarao
- Bioassay Development Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| | - Harish V Pai
- Bioassay Development Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| | - Laxmi Adhikary
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| | - Dinesh V Palanivelu
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| |
Collapse
|
12
|
Spahr CS, Daris ME, Graham KC, Soriano BD, Stevens JL, Shi SDH. Discovery, characterization, and remediation of a C-terminal Fc-extension in proteins expressed in CHO cells. MAbs 2018; 10:1291-1300. [PMID: 30148415 DOI: 10.1080/19420862.2018.1511197] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
Protein-based biotherapeutics are produced in engineered cells through complex processes and may contain a wide variety of variants and post-translational modifications that must be monitored or controlled to ensure product quality. Recently, a low level (~1-5%) impurity was observed in a number of proteins derived from stably transfected Chinese hamster ovary (CHO) cells using mass spectrometry. These molecules include antibodies and Fc fusion proteins where Fc is on the C-terminus of the construct. By liquid chromatography-mass spectrometry (LC-MS), the impurity was found to be ~1177 Da larger than the expected mass. After tryptic digestion and analysis by LC-MS/MS, the impurity was localized to the C-terminus of Fc in the form of an Fc sequence extension. Targeted higher-energy collision dissociation was performed using various normalized collision energies (NCE) on two charge states of the extended peptide, resulting in nearly complete fragment ion coverage. The amino acid sequence, SLSLSPEAEAASASELFQ, obtained by the de novo sequencing effort matches a portion of the vector sequence used in the transfection of the CHO cells, specifically in the promoter region of the selection cassette downstream of the protein coding sequence. The modification was the result of an unexpected splicing event, caused by the resemblance of the commonly used GGU codon of the C-terminal glycine to a consensus splicing donor. Three alternative codons for glycine were tested to alleviate the modification, and all were found to completely eliminate the undesirable C-terminal extension, thus improving product quality.
Collapse
Affiliation(s)
- Christopher S Spahr
- a Discovery Attribute Sciences, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| | - Mark E Daris
- b Biologics Optimization, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| | - Kevin C Graham
- b Biologics Optimization, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| | - Brian D Soriano
- a Discovery Attribute Sciences, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| | - Jennitte L Stevens
- b Biologics Optimization, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| | - Stone D-H Shi
- a Discovery Attribute Sciences, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| |
Collapse
|
13
|
Faid V, Leblanc Y, Bihoreau N, Chevreux G. Middle-up analysis of monoclonal antibodies after combined IgdE and IdeS hinge proteolysis: Investigation of free sulfhydryls. J Pharm Biomed Anal 2018; 149:541-546. [DOI: 10.1016/j.jpba.2017.11.046] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Revised: 11/10/2017] [Accepted: 11/19/2017] [Indexed: 11/28/2022]
|
14
|
Measuring protein structural changes on a proteome-wide scale using limited proteolysis-coupled mass spectrometry. Nat Protoc 2017; 12:2391-2410. [DOI: 10.1038/nprot.2017.100] [Citation(s) in RCA: 104] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
15
|
Torkashvand F, Vaziri B. Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components. IRANIAN BIOMEDICAL JOURNAL 2017; 21:131-41. [PMID: 28176518 PMCID: PMC5392216 DOI: 10.18869/acadpub.ibj.21.3.131] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/22/2016] [Revised: 11/05/2016] [Accepted: 11/08/2016] [Indexed: 11/09/2022]
Abstract
The culture media optimization is an inevitable part of upstream process development in therapeutic monoclonal antibodies (mAbs) production. The quality by design (QbD) approach defines the assured quality of the final product through the development stage. An important step in QbD is determination of the main quality attributes. During the media optimization, some of the main quality attributes such as glycosylation pattern, charge variants, aggregates, and low-molecular-weight species, could be significantly altered. Here, we provide an overview of how cell culture medium components affects the main quality attributes of the mAbs. Knowing the relationship between the culture media components and the main quality attributes could be successfully utilized for a rational optimization of mammalian cell culture media for industrial mAbs production.
Collapse
Affiliation(s)
| | - Behrouz Vaziri
- Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
| |
Collapse
|
16
|
Charge variants characterization of a monoclonal antibody by ion exchange chromatography coupled on-line to native mass spectrometry: Case study after a long-term storage at +5 °C. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1048:130-139. [DOI: 10.1016/j.jchromb.2017.02.017] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Revised: 01/20/2017] [Accepted: 02/14/2017] [Indexed: 01/20/2023]
|
17
|
Dashivets T, Stracke J, Dengl S, Knaupp A, Pollmann J, Buchner J, Schlothauer T. Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies. MAbs 2016; 8:1525-1535. [PMID: 27612038 PMCID: PMC5098445 DOI: 10.1080/19420862.2016.1231277] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Therapeutic antibodies can undergo a variety of chemical modification reactions in vitro. Depending on the site of modification, either antigen binding or Fc-mediated functions can be affected. Oxidation of tryptophan residues is one of the post-translational modifications leading to altered antibody functionality. In this study, we examined the structural and functional properties of a therapeutic antibody construct and 2 affinity matured variants thereof. Two of the 3 antibodies carry an oxidation-prone tryptophan residue in the complementarity-determining region of the VL domain. We demonstrate the differences in the stability and bioactivity of the 3 antibodies, and reveal differential degradation pathways for the antibodies susceptible to oxidation.
Collapse
Affiliation(s)
- Tetyana Dashivets
- a Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich , Germany.,b Center for Integrated Protein Science Munich , Department Chemie, Technische Universität München , Garching , Germany
| | - Jan Stracke
- c Early-Stage Pharmaceutical Development & GLP Supplies, F. Hoffmann-La Roche Ltd Pharmaceutical Development & Supplies PTD Biologics Europe , Basel , Switzerland
| | - Stefan Dengl
- a Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich , Germany
| | - Alexander Knaupp
- a Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich , Germany
| | | | - Johannes Buchner
- b Center for Integrated Protein Science Munich , Department Chemie, Technische Universität München , Garching , Germany
| | - Tilman Schlothauer
- a Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich , Germany
| |
Collapse
|
18
|
Hosken BD, Li C, Mullappally B, Co C, Zhang B. Isolation and Characterization of Monoclonal Antibody Charge Variants by Free Flow Isoelectric Focusing. Anal Chem 2016; 88:5662-9. [DOI: 10.1021/acs.analchem.5b03946] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Brian D. Hosken
- Department of Protein Analytical Chemistry, ‡Department of Biological Technologies, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Charlene Li
- Department of Protein Analytical Chemistry, ‡Department of Biological Technologies, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Berny Mullappally
- Department of Protein Analytical Chemistry, ‡Department of Biological Technologies, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Carl Co
- Department of Protein Analytical Chemistry, ‡Department of Biological Technologies, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Boyan Zhang
- Department of Protein Analytical Chemistry, ‡Department of Biological Technologies, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
19
|
An Y, Zhang Y, Mueller HM, Shameem M, Chen X. A new tool for monoclonal antibody analysis: application of IdeS proteolysis in IgG domain-specific characterization. MAbs 2015; 6:879-93. [PMID: 24927271 DOI: 10.4161/mabs.28762] [Citation(s) in RCA: 101] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Monoclonal antibody (mAb) products are extraordinarily heterogeneous due to the presence of a variety of enzymatic and chemical modifications, such as deamidation, isomerization, oxidation, glycosylation, glycation, and terminal cyclization. The modifications in different domains of the antibody molecule can result in different biological consequences. Therefore, characterization and routine monitoring of domain-specific modifications are essential to ensure the quality of the therapeutic antibody products. For this purpose, a rapid and informative methodology was developed to examine the heterogeneity of individual domains in mAb products. A recently discovered endopeptidase, IdeS, cleaves heavy chains below the hinge region, producing F(ab') 2 and Fc fragments. Following reduction of disulfide bonds, three antibody domains (LC, Fd, and Fc/2) can be released for further characterization. Subsequent analyses by liquid chromatography/mass spectrometry, capillary isoelectric focusing, and glycan mapping enable domain-specific profiling of oxidation, charge heterogeneity, and glycoform distribution. When coupled with reversed phase chromatography, the unique chromatographic profile of each molecule offers a simple strategy for an identity test, which is an important formal test for biopharmaceutical quality control purposes. This methodology is demonstrated for a number of IgGs of different subclasses (IgG1, IgG2, IgG4), as well as an Fc fusion protein. The presented technique provides a convenient platform approach for scientific and formal therapeutic mAb product characterization. It can also be applied in regulated drug substance batch release and stability testing of antibody and Fc fusion protein products, in particular for identity and routine monitoring of domain-specific modifications.
Collapse
Affiliation(s)
- Yan An
- Sterile Product and Analytical Development; Merck Research Laboratories; Kenilworth, NJ USA
| | - Ying Zhang
- Sterile Product and Analytical Development; Merck Research Laboratories; Kenilworth, NJ USA
| | - Hans-Martin Mueller
- Sterile Product and Analytical Development; Merck Research Laboratories; Kenilworth, NJ USA
| | - Mohammed Shameem
- Sterile Product and Analytical Development; Merck Research Laboratories; Kenilworth, NJ USA
| | - Xiaoyu Chen
- Sterile Product and Analytical Development; Merck Research Laboratories; Kenilworth, NJ USA
| |
Collapse
|
20
|
Michels DA, Ip AY, Dillon TM, Brorson K, Lute S, Chavez B, Prentice KM, Brady LJ, Miller KJ. Separation Methods and Orthogonal Techniques. ACS SYMPOSIUM SERIES 2015. [DOI: 10.1021/bk-2015-1201.ch005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Affiliation(s)
- David A. Michels
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Anna Y. Ip
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Thomas M. Dillon
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Kurt Brorson
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Scott Lute
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Brittany Chavez
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Ken M. Prentice
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Lowell J. Brady
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Karen J. Miller
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| |
Collapse
|
21
|
Sandra K, Vandenheede I, Sandra P. Modern chromatographic and mass spectrometric techniques for protein biopharmaceutical characterization. J Chromatogr A 2014; 1335:81-103. [DOI: 10.1016/j.chroma.2013.11.057] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2013] [Revised: 11/27/2013] [Accepted: 11/29/2013] [Indexed: 10/25/2022]
|
22
|
O-linked glucosylation of a therapeutic recombinant humanised monoclonal antibody produced in CHO cells. Eur J Pharm Biopharm 2013. [DOI: 10.1016/j.ejpb.2012.11.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
23
|
Zhang L, Patapoff T, Farnan D, Zhang B. Improving pH gradient cation-exchange chromatography of monoclonal antibodies by controlling ionic strength. J Chromatogr A 2013; 1272:56-64. [DOI: 10.1016/j.chroma.2012.11.060] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2012] [Revised: 11/18/2012] [Accepted: 11/23/2012] [Indexed: 11/25/2022]
|
24
|
Du Y, Walsh A, Ehrick R, Xu W, May K, Liu H. Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies. MAbs 2012; 4:578-85. [PMID: 22820257 DOI: 10.4161/mabs.21328] [Citation(s) in RCA: 206] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
The existence of multiple variants with differences in either charge, molecular weight or other properties is a common feature of monoclonal antibodies. These charge variants are generally referred to as acidic or basic compared with the main species. The chemical nature of the main species is usually well-understood, but understanding the chemical nature of acidic and basic species, and the differences between all three species, is critical for process development and formulation design. Complete understanding of acidic and basic species, however, is challenging because both species are known to contain multiple modifications, and it is likely that more modifications may be discovered. This review focuses on the current understanding of the modifications that can result in the generation of acidic and basic species and their affect on antibody structure, stability and biological functions. Chromatography elution profiles and several critical aspects regarding fraction collection and sample preparations necessary for detailed characterization are also discussed.
Collapse
Affiliation(s)
- Yi Du
- Merck Research Laboratories, Union, NJ, USA
| | | | | | | | | | | |
Collapse
|
25
|
Chen S, Lau H, Brodsky Y, Kleemann GR, Latypov RF. The use of native cation-exchange chromatography to study aggregation and phase separation of monoclonal antibodies. Protein Sci 2010; 19:1191-204. [PMID: 20512972 DOI: 10.1002/pro.396] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
This study introduces a novel analytical approach for studying aggregation and phase separation of monoclonal antibodies (mAbs). The approach is based on using analytical scale cation-exchange chromatography (CEX) for measuring the loss of soluble monomer in the case of individual and mixed protein solutions. Native CEX outperforms traditional size-exclusion chromatography in separating complex protein mixtures, offering an easy way to assess mAb aggregation propensity. Different IgG1 and IgG2 molecules were tested individually and in mixtures consisting of up to four protein molecules. Antibody aggregation was induced by four different stress factors: high temperature, low pH, addition of fatty acids, and rigorous agitation. The extent of aggregation was determined from the amount of monomeric protein remaining in solution after stress. Consequently, it was possible to address the role of specific mAb regions in antibody aggregation by co-incubating Fab and Fc fragments with their respective full-length molecules. Our results revealed that the relative contribution of Fab and Fc regions in mAb aggregation is strongly dependent on pH and the stress factor applied. In addition, the CEX-based approach was used to study reversible protein precipitation due to phase separation, which demonstrated its use for a broader range of protein-protein association phenomena. In all cases, the role of Fab and Fc was clearly dissected, providing important information for engineering more stable mAb-based therapeutics.
Collapse
Affiliation(s)
- Shuang Chen
- Process and Product Development, Amgen Inc., Seattle, Washington 98119, USA
| | | | | | | | | |
Collapse
|